You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for (R)-(-)-Deprenyl hydrochloride
(R)-(-)-Deprenyl hydrochloride is a selective inhibitor of monoamine oxidase B (MAO-B).
Technical Data for (R)-(-)-Deprenyl hydrochloride
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (R)-(-)-Deprenyl hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for (R)-(-)-Deprenyl hydrochloride
The following data is based on the product molecular weight 223.74. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.47 mL||22.35 mL||44.69 mL|
|5 mM||0.89 mL||4.47 mL||8.94 mL|
|10 mM||0.45 mL||2.23 mL||4.47 mL|
|50 mM||0.09 mL||0.45 mL||0.89 mL|
Product Datasheets for (R)-(-)-Deprenyl hydrochloride
References for (R)-(-)-Deprenyl hydrochloride
References are publications that support the biological activity of the product.
Gerlach et al (1992) The molecular pharmacology of L-deprenyl. Eur.J.Pharmacol. 226 97 PMID: 1639115
Kaseda et al (1999) Effect of selegeline on DA concentration in the striatum of a primate. Brain Res. 815 44 PMID: 9974121
Kotake et al (1998) Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies. Brain Res. 787 341 PMID: 9518683
Mercuri et al (1998) Modification of lev. responses by deprenyl (selegiline): an electrophysiological and behavioural study in the rat relevant to Parkinson's disease. Ann.Neurol. 43 613 PMID: 9585355
Merck Index 12 8569
If you know of a relevant reference for (R)-(-)-Deprenyl hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (R)-(-)-Deprenyl hydrochloride, (R)-(-)-Deprenyl hydrochloride supplier, MAO-B, inhibitors, inhibits, Monoamine, Oxygenases, Oxidases, parkinson's, parkinsons, Selegiline, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 1095, Tocris Bioscience
Citations for (R)-(-)-Deprenyl hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for (R)-(-)-Deprenyl hydrochloride. Do you know of a great paper that uses (R)-(-)-Deprenyl hydrochloride from Tocris? Please let us know.
Reviews for (R)-(-)-Deprenyl hydrochloride
There are currently no reviews for this product. Be the first to review (R)-(-)-Deprenyl hydrochloride and earn rewards!
Have you used (R)-(-)-Deprenyl hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.